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Background: The circadian clock and cell cycle are two global regulatory systems that have pervasive behavioral
and physiological effects on eukaryotic cells, and both play a role in cancer development. Recent studies have
indicated that the circadian and cell cycle regulator, TIMELESS, may serve as a molecular bridge between these two
regulatory systems.
Methods: To assess the role of TIMELESS in tumorigenesis, we analyzed TIMELESS expression data from publically
accessible online databases. A loss-of-function analysis was then performed using TIMELESS-targeting siRNA oligos
followed by a whole-genome expression microarray and network analysis. We further tested the effect of TIMELESS
down-regulation on cell proliferation rates of a breast and cervical cancer cell line, as suggested by the results of
our network analysis.
Results: TIMELESS was found to be frequently overexpressed in different tumor types compared to normal controls.
Elevated expression of TIMELESS was significantly associated with more advanced tumor stage and poorer breast
cancer prognosis. We identified a cancer-relevant network of transcripts with altered expression following TIMELESS
knockdown which contained many genes with known functions in cancer development and progression.
Furthermore, we observed that TIMELESS knockdown significantly decreased cell proliferation rate.
Conclusions: Our results suggest a potential role for TIMELESS in tumorigenesis, which warrants further
investigation of TIMELESS expression as a potential biomarker of cancer susceptibility and prognostic outcome.
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The circadian clock and cell cycle are two global regulatory
systems that have pervasive effects on the behavior and
physiology of eukaryotic cells. The 24-hour periodicity of
the circadian rhythm, consisting of light and dark phases
which coincide with the phases of the solar day, is main-
tained by a set of core circadian genes through a com-
plex mechanism involving transcription-translational
feedback loops [1,2]. The cell cycle is monitored by a
sequence of molecular and biochemical events including a
series of checkpoint mechanisms to ensure completion of* Correspondence: yong.zhu@yale.edu
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reproduction in any medium, provided the orbiochemical reactions unique to each phase of the cell
cycle prior to initiation of subsequent phases [3,4].
While these two regulatory systems involve distinct
mechanisms, there is evidence that they are linked and
interact at the gene, protein, and biochemical levels
[5,6]. A recent study has indicated that one circadian
regulator, TIMELESS, is also a core component of the
cell cycle checkpoint system [7]. It regulates directly or
indirectly the activity of autoregulatory components of
the mammalian circadian core, including Clock, Per, and
Cry proteins, associates with S phase replication checkpoint
proteins Claspin and Tipin, and is required for the
phosphorylation and activation of Chk1 by ATR and
ATM-dependent Chk2-mediated signaling of DNA
double strand breaks [8,9].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cycle machinery that controls cell proliferation has been
evident for some time, and there is mounting evidence
to suggest that disruption of the circadian rhythm may
increase susceptibility to certain malignancies [10-12],
little is known about TIMELESS’s role in tumorigenesis.
Our previous case–control study demonstrated significant
genetic and epigenetic associations of TIMELESS and breast
cancer risk [13]. A recent study has also shown that higher
levels of TIMELESS expression in colorectal cancer tissue is
associated with TNM stages III-IV and microsatellite
instability [14]. In contrast, findings from another
study point to the down-regulation of TIMELESS in
hepatocellular carcinomas [15].
In the current study, we report our findings from the
expression profiling analysis of TIMELESS in different
tumor types using publically available online tools and
microarray datasets, and a loss-of-function analysis using
TIMELESS-targeting siRNA oligos followed by a whole-
genome expression microarray and network analysis. We
also tested one of the potential roles of TIMELESS
suggested by our network analysis using a MTS assay
and observed that TIMELESS knockdown decreased
the proliferation rate of MCF7 breast cancer cells.
Methods
Data mining of TIMELESS expression in different tumor
types
To explore whether TIMELESS expression is altered in
different cancer types, we first performed a comprehen-
sive search using the Oncomine 4.4 online database
(https://www.oncomine.org; accessed on September 7, 2011)
[16] for expression array comparisons involving tis-
sues drawn from cancer patients and healthy controls.
The keywords used were: Gene: “TIMELESS”; Analysis
Type: “Cancer vs. Normal Analysis”. The search returned
a total of 194 analyses conducted in 93 unique studies
across various cancer types using different array platforms.
Further details regarding tissue collection and the
experimental protocol of each array are available in the
Oncomine database, or from the original publications.
We then investigated whether aberrant TIMELESS
expression was associated with tumor stage or prognostic
outcome. We searched and analyzed publicly available
microarray data sets containing tumor stage or clinical
outcome information from the Gene Expression Omnibus
(GEO) [17] and ArrayExpress databases (www.ebi.ac.uk/
arrayexpress; accessed on September 8, 2011). The cervical
cancer data set (GEO accession # GSE7803) contains gene
expression data of normal cervical tissue, high-grade
squamous intraepithelial lesions and invasive squamous
cell carcinomas [18]. The ArrayExpress breast cancer data
set (accession # E-TABM-276) examined gene expression
in malignant breast tumor tissue, adjacent tissue exhibitingcystic changes, adjacent normal breast tissue and tissue
drawn from healthy controls [19]. The prostate cancer data
set GSE8511 includes tissue from benign prostate and
localized and metastatic prostate tumor tissues [20], and
GSE21034 contains samples from normal adjacent benign
prostate and primary and metastatic prostate tumor tissues
[21]. GSE2034 examined the association between gene
expression in tissues drawn from primary breast cancer
patients and their clinical outcomes [22]. The GOBO
online tool (Gene Expression-Based Outcome for Breast
Cancer Online co.bmc.lu.se/gobo), designed for prognostic
validation of genes in a pooled breast cancer data set
comprising 1881 cases from 11 public microarray data
sets, was used to validate our analysis of the GSE2034
breast cancer data set [23].Cell culture and treatments
All experimental procedures were approved by the
Institutional Review Board at Yale University and the
National Cancer Institute. To determine TIMELESS’s
role in tumorigenesis, we then performed an in vitro
loss-of-function analysis using TIMELESS-targeting
siRNA oligos followed by a whole-genome expression
microarray. Human HeLa cells (American Type Culture
Collection, Manassas, VA) were maintained in Dulbecco’s
modified Eagle medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen) and
1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO).
Short interfering RNA (siRNA) oligonucleotides tar-
geting exon 11 of TIMELESS (Ambion ID s17053; cat.
no. 4392420) and a scrambled sequence negative con-
trol oligonucleotide were designed and manufactured
by Ambion, Inc. (Ambion/Applied Biosystems). Each
oligonucleotide was reverse-transfected in 12-well
plates with ~10,000 cells/well at a final concentration
of 10 nM using the Lipofectamine RNAiMAX transfection
reagent (Invitrogen).RNA isolation and quantification
RNA was isolated using the RNA Mini Kit (Qiagen),
with on-column DNA digestion, according to the pro-
tocols of the manufacturer for mammalian cells. RNA
was quantified using a NanoDrop spectrophotometer
(Thermo Scientific), and first-strand cDNA was synthe-
sized using the AffinityScript cDNA Kit (Stratagene) with
random ninemer primers. TIMELESS mRNA expression
was measured by quantitative real-time PCR performed in
duplicate using the Power SYBR Green PCR master
mix (Applied Biosystems) and a standard thermal
cycling procedure on an ABI 7500 instrument (Applied
Biosystems). RNA quantity was normalized using HPRT1,
and TIMELESS silencing was quantified using the 2−ΔΔCt
method.
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Gene expression differences in normal HeLa cells and those
with reduced TIMELESS levels were examined by whole
genome microarray (Agilent, Inc., 44 K chip, performed by
MoGene, LC). RNA was isolated from biological rep-
licates of each treatment condition (TIMELESS-targeting
or scrambled negative control). Gene expression fold
changes in TIMELESS knockdown cells relative to the
mock siRNA-treated negative control were determined for
each replicate. Samples with inadequate signal intensity
(i.e., intensity < 50 in both the Cy3 and Cy5 channels),
and transcripts with adjusted P-values greater than 0.05 in
either biological replicate were discarded. To further reduce
the number of false positive observations, and to enrich
for biologically relevant expression changes, the remaining
transcripts were defined as significantly differentially
expressed only if they displayed a mean fold change
in expression of at least |2|.
Pathway-based network analysis
We then interrogated the differentially expressed tran-
scripts for network and functional interrelatedness using
the Ingenuity Pathway Analysis software tool (Ingenuity
Systems; www.ingenuity.com). The software uses an exten-
sive database of functional interactions which are drawn
from peer-reviewed publications and are manually main-
tained [24]. P-values for individual networks were obtained
by comparing the likelihood of obtaining the same number
of transcripts or greater in a random gene set as are actually
present in the input set (i.e., the set of genes differentially
expressed following TIMELESS knockdown) using a
Fisher's exact test, based on the hypergeometric distribu-
tion. Our microarray data were uploaded to the Gene
Expression Omnibus [17] database (www.ncbi.nlm.nih.gov/
projects/geo/; accession # pending). The differential expres-
sion of several genes detected by the microarray was
assessed and confirmed by quantitative real-time PCR. The
primers used were designed in house and the sequences are
provided in Additional file 1: Table S1.
Cell proliferation assay
The results from our network analysis suggested us to
further investigate TIMELESS’s potential role in cellular
growth and proliferation. HeLa and MCF7 cells (American
Type Culture Collection) were reverse transfected
with siRNA oligos targeting TIMELESS and a scrambled
sequence negative control in 96-well plates using the
Lipofectamine RNAiMAX transfection reagent (Invitrogen).
Cell proliferation was analyzed in triplicate at baseline,
24 hours, 48 hours, 72 hours, and 96 hours using the
CellTiter 96® AQueous One Solution Cell Proliferation
Assay (MTS) kit (Promega Corporation, Madison, WI) and
the absorbance was measured using an Epoch microplate
spectrophotometer (BioTek, Winooski, VT).Statistical analyses
Statistical analyses were performed using the SAS statistical
software, version 9.2 (SAS Institute). Student t-tests and
one-way ANOVA were applied to calculate differences in
TIMELESS expression across different tumor stages, as
well as differences in cell proliferation rate. The log-rank
test was used to estimate the differences in survival be-
tween cancer patients with differing levels of TIMELESS
expression. Due to the multiple comparisons inherent
in our microarray analysis, adjustments were made to
control for false discoveries using the Benjamini-Hochberg
method, as previously described, to obtain a false discovery
rate-adjusted P-value for each observation (referred to as
the Q-value) [25].
Results
Overexpression of TIMELESS in different types of
tumor tissues
Searching for “TIMELESS” expression in “cancer vs.
normal” tissues in the Oncomine database returned a
total of 194 analyses from 93 unique studies across vari-
ous cancer types. 32 analyses in 20 unique studies were
identified as statistically significant with P-values < 0.01
and fold change ≥ |2|. 31 out of 32 analyses exhibited
increased TIMELESS expression in tumor relative to
normal tissues while only one showed decreased expres-
sion (Additional file 1: Table S2). A volcano plot was gener-
ated using -log10 transformed P-values and the fold change
of TIMELESS expression in tumor versus normal tissues
extracted from each analysis. The size of each circle
is proportional to the size of the analysis it corresponds to
(Figure 1A). The plot indicates that TIMELESS expression
is frequently elevated in tumor relative to normal tissues
across multiple cancer types.
Increased TIMELESS expression is associated with more
advanced tumor stage and poorer breast cancer
prognosis
To investigate whether TIMELESS expression is associated
with tumor stage and clinical outcome, we analyzed five
publicly available microarray data sets extracted from
the GEO and ArrayExpress online databases: GSE7803
(cervical cancer), GSE21034 (prostate cancer), GSE8511
(prostate cancer), GSE2034 (breast cancer), and E-TABM-
276 (breast cancer). We observed that TIMELESS expres-
sion in invasive cervical cancer tissue was significantly
higher than in normal tissue (P < 0.001) and preinvasive
cervical cancer tissue (P < 0.001) (Figure 1B). In the breast
cancer study E-TABM-276, TIMELESS expression in
breast tissue from healthy controls was significantly lower
than in invasive carcinomas (P < 0.001) or tissues exhibit-
ing cystic changes (P < 0.05). Likewise, TIMELESS expres-
sion in adjacent normal breast tissues was significantly
lower than in either invasive carcinomas or tissues with
Figure 1 (See legend on next page.)
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Figure 1 Microarray data mining of TIMELESS expression in different tumor types. (A) TIMELESS expression in tumor tissues relative to
controls from the Oncomine database. 31 out of 32 analyses showed higher TIMELESS expression while 1 analysis found lower TIMELESS
expression. Analyses exhibiting P-values < 0.01 and fold-change values≥ |2| are marked in red and green respectively. The size of each circle is
scaled by the sample size of the corresponding analysis. (B) TIMELESS expression in cervical cancer tissue versus preinvasive and normal tissue.
Expression of TIMELESS in invasive cervical cancer tissues is significantly higher than in either normal or preinvasive tumor tissues. The original
array data are from the Gene Expression Omnibus (accession # GSE7803). (C) TIMELESS expression in breast tumor, adjacent tissues and tissues from
healthy controls. TIMELESS expression in breast tissue from healthy controls and adjacent normal tissue was significantly lower than in invasive
carcinomas or tissues exhibiting nonproliferative change (cystic change). Original array data is from the ArrayExpress database (accession # E-TABM-276).
(D) and (E) TIMELESS expression in prostate tumor and normal tissues. In normal prostate tissue, TIMELESS expression is significantly lower than in primary
prostate tumor and metastatic tumor tissues. Metastatic tumor tissue exhibited the highest TIMELESS expression level compared to the other two groups.
Original array data are from the Gene Expression Omnibus database (accession #'s GSE21034 and GSE8511).
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(Figure 1C). Similarly, in both of the two prostate
cancer studies, significantly increased TIMELESS expres-
sion was observed in metastatic tumor tissue com-
pared to primary prostate tumor tissue and benign
tissue (Figure 1D and E).Figure 2 Kaplan-Meier survival analysis of TIMELESS expression using
1881 breast cancer cases from 11 public data sets. Samples were strati
was performed in all tumor samples as well as in different tumor subtypes
High TIMELESS expression is significantly associated with lower DMFS over
(P = 1.65E-3), (B) cases with ER-positive tumors (P = 2.20E-4), (C) cases with
LN-negative tumors (P = 1.00E-5).Analyzing the lymph node-negative breast cancer data
set of GSE2034, we found that patients with lower
TIMELESS expression levels were more likely to have a
higher rate of distant metastasis-free survival (DMFS)
(P < 0.05). Interrogating TIMELESS expression using
the GOBO database revealed similar results: increasedthe GOBO online tool, which comprises of pooled data from
fied into tertiles based on TIMELESS expression level. The log-rank test
using distant metastasis-free survival (DMFS) as the endpoint.
time among (A) all cases regardless of tumor ER- and LN-positivity
LN-negative tumors (P = 9.00E-5), and (D) cases with ER-positive and
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rate not only in the general breast tumor population
(P < 0.005), but also in tumor subtypes, including
lymph node-negative (P < 0.001), ER-positive (P < 0.001),
and lymph node- negative ER-positive (P < 0.001) breast
tumors (Figure 2).
Cancer-relevant network formed by TIMELESS-influenced
genes
To explore TIMELESS’s potential functional significance
in regulating cancer-relevant gene networks, we per-
formed a loss-of-function analysis using TIMELESS-
targeting siRNA oligos, followed by a whole genome
expression microarray and subsequent network analysis.
Prior to the microarray, TIMELESS knockdown was con-
firmed using quantitative RT-PCR. TIMELESS mRNA
levels were reduced by more than 90% following knock-
down (P < 0.01) (Additional file 2: Figure S1). In the array,
660 transcripts fit our significance criteria for differential
expression following TIMELESS knockdown (Q < 0.05 andFigure 3 The IPA-generated network most significantly associated wi
Ingenuity Pathway Analysis tool, the network is relevant to “cellular movem
were upregulated following TIMELESS knockdown are shaded in red, while
intensity signifying the relative magnitude of change. Each interaction is su
Pathway Knowledge Base, with solid lines representing direct interactions,mean fold change ≥ |2|). Validation of differential expres-
sion was performed on nine genes using quantitative real-
time PCR (Additional file 2: Figure S2). This gene set was
examined for functional interrelatedness using the Ingenu-
ity Pathway Analysis software tool. Cancer was identified
as the top disease significantly associated with the input
gene set, while cellular movement, development, and
growth and proliferation were identified as the top three
molecular and cellular functions.
Thirteen functional networks were identified as being sig-
nificantly associated with the input gene set (P < 1.0E-10),
the majority of which are cancer-related (Additional file 1:
Table S3). The top functional network (P = 1.0E-32,
Figure 3) formed by TIMELESS-affected genes was
defined as having relevance for “cellular movement,
immune cell trafficking, [and] gene expression”. Every
one of the twenty-six genes within this top network
has been reported to be involved in carcinogenesis or
tumor progression. Among them, CXCL1 [26], EDN1 [27],
EPAS1 [28,29], GDP15 [30,31], IL8 [32,33], KRT17 [34,35],th genes affected by TIMELESS knockdown. According to the
ent, immune cell trafficking, [and] gene expression”. Transcripts that
transcripts that were downregulated are shaded in green, with color
pported by at least one literature reference identified in the Ingenuity
and dashed lines representing indirect interactions.
Table 1 Molecules in the top (P = 1.0E-32) network of genes differentially expressed following TIMELESS knockdown
Symbol RefSeq Description Fold change Q-Value
BMP7 AL567265 Growth factor, may play a role in early development 2.41 5.2E-05
CRKL NM_005207 Activates the RAS and JUN kinase signaling pathways
and transform fibroblast in RAS-dependent fashion,
candidate oncogene
-3.04 3.3E-06
CXCL1 NM_001511 Chemokine (C-X-C motif) ligand 1, regulates cell
trafficking
2.10 1.4E-04
DMBT1 NM_007329 Plays a role in the interaction of tumor cells and the
immune system, candidate tumor suppressor
-5.26 1.3E-12
DTL NM_016448 Denticleless homolog (Drosophila), required for cell
cycle control, DNA damage response and translesion
DNA sythesis
-2.34 2.0E-11
EDN1 NM_001955 Endothelin 1, growth factor, involved in tumor
progression
4.26 5.8E-32
EMP1 BC017854 Endothelia membrane protein 1 5.33 7.1E-13
EPAS1 NM_001430 Endothelia PAS domain protein 1, transcription
factor, involved in the induction of genes regulated
by oxygen
3.21 6.7E-11
EPHB6 NM_004445 EPH receptor B6, modulates cell adheson and
migration, mediates numerous developmental
processes, particularly in the nervous system.
-2.62 2.9E-05
GOS2 NM_015714 G0/G1 switch regulatory protein 2, potential oncogene 3.37 3.8E-09
GDF15 NM_004864 Growth differentiation factor 15, member of the
transforming growth factor-beta superfamily,
regulates tissue differentiation and maintenance
4.49 3.5E-12
IL8 NM_000584 Interleukin 8, cytokine, inhibits the proliferation of
tumor cells
5.10 1.7E-11
KDM3A NM_018433 May play a role in hormone-dependent transcription
acivation and histone code, involved in spermatogenesis
and obesity resistance
-2.13 1.5E-08
KRT17 NM_000422 Type I intermediate filament chain keratin 17, may be
a marker for basal cell differentiation in complex epithelia
3.45 1.1E-07
LIFR NM_002310 Leukemia inhibitory factor which is involved in cellular
differentiation, proliferation and survival
2.77 2.7E-11
OSM NM_020530 Cytokine, inhibits the proliferation of a number cell lines 3.23 1.5E-06
PKIA NM_006823 Protein kinase inhibitor alpha -3.30 7.2E-09
PODXL NM_005397 Podocalyxin-like, involved in regulation of both adhesion
and cell morphology and cancer progression
-2.47 3.5E-06
PTGFR NM_000959 Prostaglandin F receptor 5.31 1.1E-08
RGS20 NM_170587 Regulation of G-protein signaling 20, accelarate transit
through the cycle of GTP binding and hydrolysis and
thereby accelerate signaling kinetics and termination
-3.34 3.4E-08
RHOB NM_004040 Mediates apoptosis in neo plastically transformed cells
after DNA damage, affects cell adhesion and growth
factor signaling in transformed cells, involved in
intracellular protein trafficking of a number of proteins
2.16 1.2E-04
SOD2 BC016934 Member of the iron/manganese superoxide dismutase
family potential tumor suppressor
15.90 2.1E-14
TFPI2 ENST00000222543 Tissue factor pathway inhibitor 2, may play a role in
the regulation of plasmin-mediated matrix remodeling
-5.19 4.9E-12
TNFRSF4 NM_003327 Tumor necrosis factor receptor superfamily, member 4,
may suppresses apoptosis, plays a role in T cells-dependent
B cell proliferation and differentiation
-2.09 8.6E-03
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Table 1 Molecules in the top (P = 1.0E-32) network of genes differentially expressed following TIMELESS knockdown
(Continued)
TNFSF4 NM_003326 Tumor necrosis factor (ligand) superfamily, member 4,
directly mediates adhesion of activated T cells to
vasular endothelial cells
2.18 6.9E-04
TSLP NM_033035 Thymic stromal lymphopoietin, induces release of T
cell-attracting chemokines from monocytes and
enhances the maturation of CD11c(+) dendtritic cells
-4.68 8.0E-09
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PODXL [41], RGS20 [42], and TSLP [43] are observed to
be frequently overexpressed in cancer cells and are sug-
gested to be involved in cancer development, tumor pro-
gression or poorer prognostic outcome. In contrast, SOD2
[44,45], RHOB [46,47], G0S2 [48], EMP1 [49], TNFRSF4
[50], TNFSF4 [51], DMBT1 [52,53], LIFR [54], TFPI2 [55],
and EPHB6 [56] are frequently down-regulated in
cancer and may be associated with tumor suppression
or favorable prognostic outcome. A summary of the
genes in this network, along with a brief description
of relevant functions, Q-values and fold changes following
TIMELESS knockdown, is presented in Table 1.
TIMELESS knockdown decreases breast cancer cell
proliferation rate
As suggested by the findings of our network analysis, we
tested TIMELESS’s potential role in cellular growth and pro-
liferation using a MTS assay. As shown in Figure 4, transfec-
tion with TIMELESS-targeting siRNA oligos significantly
decreased MCF7 cell growth compared to untreated MCF7
cells (P < 0.05) and negative control cells (P < 0.05). A similar
trend was observed with HeLa cells, but only a slight, yet not
statistically significant, decrease in proliferation rate was
observed compared to negative control cells (P= 0.156).
Discussion
Since the hypothesis linking circadian disruption to in-
creased breast cancer risk was first proposed twenty years
ago, there have been many molecular epidemiologic studies
implicating the tumorigenic importance of circadian varia-
tions, including genetic and epigenetic variations, and aber-
rant gene expression [10,57,58]. TIMELESS, which regulates
directly or indirectly the activity of autoregulatory compo-
nents of the mammalian circadian core, has been shown to
play an essential role in the cell cycle checkpoint response
[8,9]. As a potential molecular bridge between the cell cycle
and the circadian regulatory systems, TIMELESS is also
likely to play a significant role in tumorigenesis.
In our previous breast cancer case–control study, we
found significant associations between two tagging SNPs
in the TIMELESS gene and decreased breast cancer suscep-
tibility. TIMELESS promoter hypomethylation in peripheral
blood lymphocytes was also found to be significantly associ-
ated with later-stage breast cancer. In the current study, weobserved that TIMELESS is frequently overexpressed in
tumor relative to normal tissues in several cancer types,
and that elevated expression of TIMELESS is signifi-
cantly associated with later tumor stages and poorer
breast cancer prognosis. Our findings also provide the
first evidence suggesting the diagnostic and prognostic
potential of TIMELESS in cancer.
Intriguingly, all 26 genes in the top IPA-generated
network have been reported to be involved in cancer.
G0S2 (3.37-fold increase), which encodes a mitochondrial
protein that specifically interacts with Bcl-2, is a proapop-
totic factor, and its ectopic expression induces apoptosis in
diverse human cancer cell lines in which endogenous G0S2
is normally epigenetically silenced [48]. Similarly, RhoB
(2.16-fold increase) is a well-characterized small GTPase
that can inhibit cell proliferation, survival and invasion,
and it is often down-regulated in cancer cells [47]. EMP1
(5.33-fold increase) encodes a potential tumor suppressor
that is associated with cellular proliferation and metastasis
[49]. DMBT1 (Deleted in malignant brain tumors 1 protein)
(5.26-fold decrease) is a putative tumor suppressor gene
frequently deleted in brain, gastrointestinal and lung
cancers and down-regulated in breast cancer and prostate
cancer [59]. Interestingly, Superoxide dismutase (SOD2), a
probable tumor suppressor responsible for the destruction
of superoxide free radicals [44], displayed a 15.9-fold
increase in expression following TIMELESS knockdown.
Additionally, Endothelin-1 (EDN1) (4.26-fold increase)
encodes a growth factor that is frequently produced
by cancer cells and plays a key role in cell growth,
differentiation, apoptosis, and tumorigenesis [27]. Bone
Morphogenetic protein 7 (BMP7) (2.41-fold increase), also
known as osteogenic protein 1 (OP-1), encodes a multi-
functional growth factor belonging to the TGF-β superfam-
ily. Elevated BMP7 levels are reported to be correlated with
the depth of colorectal tumor invasion, liver metastasis and
cancer-related death [60], as well as the levels of estrogen
and progesterone receptor, both of which are important
markers for breast cancer prognosis and therapy [61]. Simi-
larly, GDF15 (4.49-fold increase), which encodes another
member of the TGF-β superfamily, was reported to exert
proapoptotic and anti-tumorigenic functions on colorectal,
prostate, and breast cancer cells in vitro and on colon and
blioblastoma tumors in vivo [62]. IL8 (5.1-fold increase) has
also been reported to have functions in the regulation of
Figure 4 MCF7 and HeLa cell proliferation rates were assessed
at baseline, 24 hours, 48 hours, 72 hours, and 96 hours
following transfection with a TIMELESS siRNA and a scrambled
sequence negative control oligo. (A) Transfection with TIMELESS
siRNA in MCF7 cells slowed down cell proliferation compared to
negative controls (P < 0.05); (B) TIMELESS knockdown did not result
in a significant reduction in cell proliferation rate in HeLa cells.
Error bars represent standard deviations.
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and modification of immune responses [63]. These data
suggest that loss of TIMELESS expression has the poten-
tial to influence a set of cancer-relevant genes, although
most of these genes showing altered expression may not
interact directly with TIMELESS. However, without further
mechanistic investigations, it is not possible to identify
whether these transcripts are direct or indirect targets of
TIMELESS.
Timeless, together with its constitutive binding partner,
Tipin, functions as a replisome-associated protein which
interacts with components of the endogenous replicationfork complex [64]. Moreover, siRNA-mediated TIMELESS
down-regulation attenuates DNA replication efficiency
[64]. Consistent with this observation, we observed a
significant decrease in MCF7 cell proliferation after
TIMELESS knockdown. However, we found only a slight
but non-significant decrease in cell proliferation in HeLa
cells following TIMELESS knockdown. This latter obser-
vation is consistent with the finding that TIMELESS
down-regulation did not have a significant effect on cell
proliferation in HeLa cells previously reported by Masai
et al. [65]. As a recent study conducted by Engelen et al.
revealed elevated TIMELESS expression in tissues under-
going active proliferation, the implication is that increased
TIMELESS expression may be a characteristic of all highly
proliferative cells, rather than one exclusive to cancer
tissues. However, this relationship does not necessarily
diminish the significance of TIMELESS in cancer simply
because heightened cellular proliferation can be an im-
portant driver of the cancerous state. Even if TIMELESS
expression is elevated as a result of, rather than a precur-
sor to, heightened proliferation, TIMELESS expression
may represent a natural response to abnormal proliferative
rates and its potential physiological significance in cancer
cannot be discounted. Further mechanistic studies are
needed to investigate the precise role of TIMELESS on
cellular growth and proliferation in different cancer types,
as well as the capacity of TIMELESS to influence other
potentially cancer-relevant pathways, including cell motility,
invasiveness, and DNA damage response.
Although initial screening found a similar anti-proliferative
response to a second siRNA, only the siRNA that conferred
the greater phenotypic effect was chosen for subsequent
assays. Given the inherent difficulty in controlling for off-
target effects in any knockdown experiment performed
using a single siRNA, the results presented here should be
subjected to independent validation with use of a second
siRNA. Furthermore, there is evidence to suggest that the
anti-proliferative response observed from TIMELESS silen-
cing could be partly attributable to apoptosis. It is evident
that proliferation of transfected cells plateaus between the
48 hour and 72 hour time points and decreases thereafter,
marking a period of gradual cell death. The degree to
which silencing of TIMELESS elicits an apoptotic response
should be the subject of a future investigation.
Conclusions
In summary, these findings, although preliminary, support
the findings from our previous breast cancer case–control
study, and provide further evidence of the link between
TIMELESS and carcinogenesis. The expression profiling
analysis of the tissue-specific microarray data suggests that
TIMELESS is frequently overexpressed in various types of
tumor tissues, and elevated TIMELESS expression is associ-
ated with advanced tumor stage and poorer breast cancer
Mao et al. BMC Cancer 2013, 13:498 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/498prognosis. These data, in conjunction with the findings
from the network analysis and the cell proliferation assay,
suggest TIMELESS may be involved in the tumorigenic
process. However, further mechanistic investigations are
warranted to further elucidate the precise role of TIMELESS
in tumorigenesis, and to help in the development of
targeted therapeutic strategies.
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